封面
市场调查报告书
商品编码
1087029

全球神经功能替代市场预测(2022-2027)

Global Neuroprosthetics Market - Forecasts from 2022 to 2027

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 130 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球神经替代市场预计将从 2020 年的 32.08 亿美元增长到 2027 年的 72.17 亿美元,复合年增长率为 12.28%。

全球神经病变发病率的增加是预计在预测期内推动全球神经替代品市场增长的关键因素之一。此外,随着糖尿病患者人数的增加和神经损伤患者人数的增加,预计未来几年对神经功能替代品的需求将激增。此外,听力受损人群的数量逐年显着增加,预计未来几年将激增,进一步推动全球神经替代市场在评估期内的增长。

本报告调查了全球神经功能替代市场,并提供了市场概况、市场驱动因素和限制、类型/技术/用途/区域分析、竞争形势、公司概况等。

目录

第1章介绍

  • 市场定义
  • 市场细分

第2章调查方法

  • 调查数据
  • 先决条件

第 3 章执行摘要

  • 调查重点

第4章市场动态

  • 市场促进因素
  • 市场製约因素
  • 波特五力分析
    • 终端用户议价能力
    • 买方的议价能力
    • 新进入者的威胁
    • 替代威胁
    • 行业竞争形势
  • 产业价值链分析

第 5 章全球神经功能替代市场分析:按类型

  • 简介
  • 替代输出神经函数
  • 输入神经函数替代

第 6 章全球神经功能替代市场分析:按技术

  • 简介
  • 深部脑刺激
  • 脊髓刺激法
  • □神经刺激法
  • 经颅磁刺激
  • 不明神经刺激

第 7 章全球神经功能替代市场分析:按应用

  • 简介
  • 听觉处理障碍
  • 帕金森病
  • 癫痫
  • 眼科疾病
  • 心血管疾病
  • 瘫痪
  • 阿尔茨海默病
  • 其他

第 8 章全球神经功能替代市场分析:按地区

  • 简介
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 其他
  • 中东/非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 其他
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 台湾
    • 泰国
    • 印度尼西亚
    • 其他

第9章竞争环境与分析

  • 主要公司及战略分析
  • 初创企业和市场优势
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第 10 章公司简介

  • SenArs
  • LivaNova PLC
  • Medtronic PLC
  • Sonova Holding AG
  • Boston Scientific Corporation
  • Cochlear Ltd
  • Demant AS
  • Abbott Laboratories
  • NeuroPace, Inc.
  • BrainGate
  • NDI Medica
简介目录
Product Code: KSI061612097

The global neuroprosthetics market was evaluated at US$3.208 billion in the year 2020 and is projected to grow at a CAGR of 12.28% to reach a market size of US$7.217 billion by the year 2027.

Neuroprosthetics are devices that are implanted in patients having neural damage to compensate for and restore the normal functioning of the nerves, which consequently help in partially restoring normal bodily functions. The rising incidences of neurological disorders worldwide is one of the major factors anticipated to boost the growth of the global neuroprosthetics market during the forecast period. Furthermore, the growing number of diabetes patients, leading to nerve damage in many people, is also expected to lead to a surge in demand for neuroprosthetics in the coming years. Moreover, the number of people with disabling hearing loss has been increasing substantially over the years, and its projected rapid rise in the coming years is further anticipated to augment the growth of the global neuroprosthetics market during the assessment period.

The COVID-19 pandemic had a negative impact on the global neuroprosthetics market as access to healthcare was limited for non-COVID patients during the peak of the coronavirus outbreak. The focus of the healthcare system was shifted to COVID-19 patients due to a huge number of mortalities. This led to a decrease in the diagnosis and treatment of patients with disabling hearing loss, neurological disorders, and patients with other conditions requiring the use of neuroprosthetics. This led to a decrease in the demand for neuroprosthetics during the pandemic, which resulted in a decline in the market growth in 2020.

Rising cases of neurological disorders

The number of people suffering from neurological disorders is on the rise worldwide and is one of the prominent reasons anticipated to drive the demand for neuroprosthetics during the forecast period. According to World Health Organization, the number of deaths caused by neurological disorders has increased by nearly 39% in the last 30 years. It has also been stated that an increase in the number of patients with neurological disorders is being seen over the years, while the number of cases is further projected to grow in the coming years owing to a growing elderly population, a decrease in child mortality, and rise in the survival rate and life expectancy. As per data from the PAHO, the years lived with disability (YLDs) per 100,000 population in Brazil has increased from 784.06 years in 2010 to 813.74 years in 2019. In Mexico, it increased from 721.78 years in 2010 to 737.02 years in 2019. In the United States, the deaths from neurological disorders increased from 39.29 deaths per 100,000 population in 2010 to 47.39 deaths in 2019, witnessing an increase of more than 20%. The diseases such as Alzheimer's, dementia, and Parkinson's disease are some of the neurological disorders spreading fast. For instance, as per Pan America Health Organization, Canada has witnessed a surge in the disability-adjusted life years (DALYs) per 100,000 population from 351.30 in 2010 to 415.70 in 2019, growing by more than 18%.

Growing prevalence of hearing loss

As neuroprosthetics are used in severe hearing loss, the increasing prevalence of hearing loss worldwide is a significant factor expected to augment the growth of the global neuroprosthetics market in the coming years. According to data from the WHO, the absolute number of people with hearing loss in Brazil has increased from 10 million in 2008 to 13 million in 2018. In China, the number has increased from 74 million in 2008 to 96 million in 2018, while in India, the number of people with hearing loss increased from 76.5 million in 2008 to 100 million in 2018. WHO has projected that people with disabling hearing loss will increase from 430 million in 2020 to more than 700 million by 2050. This is expected to surge the demand for neuroprosthetics significantly.

North America projected to have a major market share

Geographically, the North American region is anticipated to hold a significant market share owing to the rising cases of neurological disorders in the region, especially in the United States. Furthermore, the presence of a quality healthcare system and its accessibility to the patients makes the diagnosis and treatment stronger, which is another prominent reason for the large market size of neuroprosthetics in the region. The Asia Pacific region is anticipated to witness substantial growth due to the rising prevalence of hearing loss in the region. According to data from the WHO, the absolute number of people with disabling hearing loss in South Asia is projected to increase from 131 million in 2018 to 176 million in 2030 and further to 267 million in 2050. Furthermore, the rapidly growing cases of diabetes in the region are leading to damage to the nerves and blood vessels of a large number of patients, which is further projected to surge the demand for neuroprosthetics in the Asia Pacific region during the assessment period.

Segmentation

  • By Type

Output Neural Prosthetics

Input Neural Prosthetics

  • By Technique

Deep Brain Stimulation

Spinal Cord Stimulation

Sacral Nerve Stimulation

Transcranial Magnetic Stimulation

Vague Nerve Stimulation

  • By Application

Auditory Processing Disorders

Parkison's Disease

Epilepsy

Ophthalmic Disease

Cardiovascular Disease

Paralysis

Alzheimer's Disease

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • Germany
  • France
  • UK
  • Others

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Others

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Neuroprosthetics Market Analysis, by Type

  • 5.1. Introduction
  • 5.2. Output Neural Prosthetics
  • 5.3. Input Neural Prosthetics

6. Global Neuroprosthetics Market Analysis, by Technique

  • 6.1. Introduction
  • 6.2. Deep Brain Stimulation
  • 6.3. Spinal Cord Stimulation
  • 6.4. Sacral Nerve Stimulation
  • 6.5. Transcranial Magnetic Stimulation
  • 6.6. Vague Nerve Stimulation

7. Global Neuroprosthetics Market Analysis, by Application

  • 7.1. Introduction
  • 7.2. Auditory Processing Disorders
  • 7.3. Parkison's Disease
  • 7.4. Epilepsy
  • 7.5. Ophthalmic Disease
  • 7.6. Cardiovascular Disease
  • 7.7. Paralysis
  • 7.8. Alzheimer's Disease
  • 7.9. Others

8. Global Neuroprosthetics Market Analysis, by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. UK
    • 8.4.4. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles 

  • 10.1. SenArs
  • 10.2. LivaNova PLC
  • 10.3. Medtronic PLC
  • 10.4. Sonova Holding AG
  • 10.5. Boston Scientific Corporation
  • 10.6. Cochlear Ltd
  • 10.7. Demant AS
  • 10.8. Abbott Laboratories
  • 10.9. NeuroPace, Inc.
  • 10.10. BrainGate
  • 10.11. NDI Medica